A 17p11.2 germline deletion in a patient with Smith-Magenis syndrome and neuroblastoma

Published in:
Journal of Medical Genetics

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
A 17p11.2 germline deletion in a patient with Smith-Magenis syndrome and neuroblastoma

T Hienonen, H Sammalkorpi, P Isohanni, R Versteeg, R Karikoski and L A Aaltonen

J. Med. Genet. 2005;42:3-
doi:10.1136/jmg.2004.022814

Updated information and services can be found at:
http://jmg.bmj.com/cgi/content/full/42/1/e3

These include:
References
This article cites 27 articles, 6 of which can be accessed free at:
http://jmg.bmj.com/cgi/content/full/42/1/e3#BIBL

Rapid responses
You can respond to this article at:
http://jmg.bmj.com/cgi/eletter-submit/42/1/e3

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the
top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections
Genetics (3952 articles)

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to Journal of Medical Genetics go to:
http://www.bmjournals.com/subscriptions/
Neuroblastoma is the most frequently occurring extra-cranial tumour type in children. It arises from the undifferentiated neural crest derived cells destined to become the sympathetic nervous system, and primary tumours typically occur in the adrenal medulla and paraspinal location in the abdomen or chest. At diagnosis, most children of >1 year of age have metastases, commonly in lymph nodes, bones, or bone marrow. However, in addition to potential lethal progression, neuroblastomas occasionally mature into benign ganglioneuromas or spontaneously regress, even without treatment.¹ ²

Several acquired genetic changes have been described in neuroblastoma, the most frequent being MYCN oncogene amplification, 1p deletion, and 17q amplification.³ These alterations have been associated with aggressive forms of the disease; MYCN amplification in particular is used as a prognostic marker. In addition, chromosome number changes, translocations, and deletions in several other parts of the genome have been identified, but the significance of these changes needs further clarification.

A small subset of neuroblastoma cases have a family history of the disease and are diagnosed at a younger age with multifocal primary tumours.⁴ Hence Knudson and Strong postulated that the two hit model of cancer initiation could be applied to neuroblastoma, and that the mode of inheritance was consistent with autosomal dominant Mendelian pattern with incomplete penetrance.

Some linkage studies have been performed on familial neuroblastomas, and linkage to 4p16 and 16p12-13 has been suggested in families from Europe and North America, respectively.⁵ ⁶ However, the chromosome 16p region was tested for linkage with negative results in Italian and British families.⁷ ⁸ In addition, the known candidate neuroblastoma loci that are frequently altered sporadically have been excluded in some neuroblastoma families.⁹ ¹⁰ Thus, despite extensive studies into neuroblastoma susceptibility, the putative predisposing genetic changes have remained unidentified, and additional analyses are required to further elucidate the mechanisms behind hereditary neuroblastoma development.

We report the genetic analyses of a Finnish girl who was diagnosed with neuroblastoma at the age of 2 years and 10 months. At diagnosis, she had advanced stage neuroblastoma, but with extensive therapy, she was cured of the disease. She was subsequently diagnosed with a psychomotor retardation/multiple congenital anomaly syndrome, Smith-Magenis syndrome (SMS), which was confirmed by karyotyping; the patient displayed a 17p11.2 germine deletion, characteristic of this syndrome. Because of the possible association of the neuroblastoma and the germine deletion, 17p11.2 was further evaluated in the patient's normal tissue DNA by array comparative genomic hybridization (CGH).

We report the genetic analyses of a Finnish girl who was diagnosed with an advanced stage neuroblastoma at the age of 34 months. The patient was also diagnosed with Smith-Magenis syndrome at 9 years of age, and a germline deletion in 17p11.2 was detected as the underlying cause. Because of the possible association of the neuroblastoma and the germine deletion, 17p11.2 was further evaluated in the patient's normal tissue DNA, and in sporadic neuroblastomas and neuroblastoma cell lines.

Using microsatellite marker analysis in the patient's normal tissue DNA, the 17p11.2 deletion was found to span 4.2 Mb between markers D17S1857 and D17S842. Altogether, 11 sporadic neuroblastomas were analysed for loss of heterozygosity in the deleted region, but no allelic imbalance was detected. No other copy number changes were detected in the patient's normal tissue DNA by array comparative genomic hybridization.

Data from serial analysis of gene expression on neuroblastoma cell lines revealed that five genes in the deleted 17p11.2 region might have a role in neuroblastoma development. Of the identified genes, Ubb and Usp22 are involved in protein degradation, while Tom1l2, Mfap4, and Prps2ap2 have functions related to protein trafficking, cell adhesion, and synthesis of nucleotides, respectively.

Studying a more extensive series of neuroblastomas can help assess the importance of the affected region and the candidate genes.

METHODS

The primary tumour (stage IV) was in the left adrenal medulla and dense metastasis in the bone marrow was detected. Amplification at the MYCN locus was detected by...
fluorescence in situ hybridisation (FISH). With extensive treatment including surgery, chemotherapy, radiotherapy, and stem cell transfusion, she was cured and has remained disease free since, being 11 years of age at present. At the age of 9 years, the patient was diagnosed with SMS, characterised by psychomotor retardation, craniofacial dysmorphism, behavioural abnormalities such as aggressive and self-destructive behaviour, and multiple organ anomalies, including cardiovascular, genitourinary, and ophthalmic anomalies.15 16 She had normal early development, but strabismus was noted at 6 months of age and speech delay at the time of neuroblastoma diagnosis. Brain MRI at the age of 3 years showed bilateral subependymal nodular heterotopia, and at 5 years of age mild psychomotor retardation was obvious. The patient has major behavioural and sleep disturbances, and shows typical dysmorphic features of SMS, including brachycephaly, flat mid-face, prominent jaw, and large mouth. Her parents and brother are healthy, but her sister has been diagnosed with a heart malformation (atrioventricular septal defect).

To confirm the SMS diagnosis, the patient’s lymphocytes were screened for chromosomal aberrations with 550 band accuracy. The karyotype was normal apart from a deletion in chromosome 17p11.2. To complete the SMS diagnostic procedures, the result was confirmed by FISH.

To fine map the deleted region, microsatellite markers spanning 17p11.2 were chosen based on Ensembl database (http://www.ensembl.org/) or designed based on the sequence data. We performed microsatellite marker analysis on the normal tissue DNA of the patient and the parents. PCR conditions and primer sequences are available upon request. PCR products were run on an ABI Prism 377 DNA sequencer (Applied Biosystems, Branchburg, NJ, USA) according to the manufacturer’s instructions, and the collected data were analysed by GeneScan 3.1 and Genotyper 2.5 software (Applied Biosystems).

To further assess the deleted region we analysed the patient’s normal tissue DNA with array CGH. The hybridisations (using an Agilent Human 1 cDNA Microarray kit) were performed by the Biomedicum Biochip Center, Helsinki, Finland, according to the procedures of Monni et al.11

To identify those 17p11.2 genes that could have a role in known neuroblastoma differentiation pathways, neuroblastoma SAGE data was scrutinised. More specifically, we studied the pathways of MYCN and Meis1, which are amplified in a subset of neuroblastomas,12 13 and of TrkA, the expression of which is associated with neuroblastomas with good prognosis.14 The SAGE data was acquired by transfecting neuroblastoma cell lines SH-EP, SJ-NB8, and SH-SY5Y with MYCN, Meis1, or TrkA, respectively. The downstream pathways of the transfected genes were analysed by high throughput mRNA expression profiling. A set of SAGE libraries was constructed from the transfected and untransfected cells, and the libraries were analysed for differentially expressed genes.15 16

In addition, we analysed 11 sporadic neuroblastomas and corresponding normal tissue samples for LOH using microsatellite markers in the deleted region.

RESULTS

Chromosomal analyses on the patient’s lymphocytes performed in a diagnostic setting showed a deletion in 17p11.2 (46,XX,del(17)(p11.2p11.2)). The finding was confirmed by FISH with an FLI1 probe (del(17)(p11.2p11.2) (MDCR4,FLI1−)). We fine mapped the affected region with microsatellite marker analysis, and the deletion was shown to lie between markers D17S1857 and D17S842. These markers delineate the deletion, as they displayed heterozygosity in the patient’s normal tissue DNA.

Figure 1 Normal tissue DNA of the mother (A), patient (B), and father (C) analysed with marker D17S976. The maternal allele is absent from the patient’s DNA.

Altogether, 12 markers were examined between these two markers, five of which were informative and showed a deletion of the other allele (fig 1). The deleted interval corresponds to a 4.2 Mb distance (Ensembl, 22nd July 2004 update). Genes spanning the deleted region are presented in table 1. According to microsatellite analysis, there were no deletions in the DNA of the patient’s parents, and the deleted allele was maternal.

The normal tissue DNA of the patient was analysed by array CGH. The results correlated with the microsatellite marker data in that the deleted region contained genes with nearly 50% intensity reduction. According to the array CGH, there were no other clear areas with copy number changes in the patient’s normal tissue DNA, a finding compatible with the karyotyping result. Most of the successfully hybridised genes within the deletion have unknown functions.

The affected 17p11.2 region harbours at least 83 genes (table 1). To identify those genes that could have a role in neuroblastoma differentiation, we analysed MYCN, Meis1, and TrkA regulated gene expression in three neuroblastoma cell lines by SAGE. This approach identified a few hundred genes in the downstream pathways of MYCN, Meis1, and TrkA. In the 17p11.2 region, five genes displayed changes in their expression patterns. MYCN decreased the expression of Ubb and Tom1l2, whereas Prpap2, Mfap4, and Usp22 were down-regulated by Meis1. Mfap4 expression was also up-regulated by TrkA (table 2).

We also studied 11 sporadic normal/tumour tissue neuroblastoma samples for LOH by microsatellite marker analysis. We performed analysis on four markers in the deleted region but none of the samples showed allelic imbalance at these markers according to two independent observers. At least two, typically three, markers were informative in each normal/tumour sample pair.
<table>
<thead>
<tr>
<th>Ensembl gene ID</th>
<th>External gene ID</th>
<th>Gene description</th>
<th>Protein family description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSG00000170315.1</td>
<td>UBB</td>
<td>Ubiquitin</td>
<td>40S ribosomal s27a</td>
</tr>
<tr>
<td>ENSG00000154050.1</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000154051.1</td>
<td>NM_030970</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000175061.1</td>
<td>NM_152350</td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000181350.1</td>
<td>Q8NAA5</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000141040.3</td>
<td>ZNF287</td>
<td>Zinc finger protein 287</td>
<td>Zinc finger</td>
</tr>
<tr>
<td>ENSG00000181186.3</td>
<td></td>
<td></td>
<td>Arginine/serine rich pre-splicing factor</td>
</tr>
<tr>
<td>ENSG00000170187.2</td>
<td></td>
<td></td>
<td>Ankyrin repeat domain</td>
</tr>
<tr>
<td>ENSG00000170160.1</td>
<td>O60311</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000183855.1</td>
<td></td>
<td></td>
<td>UPF3</td>
</tr>
<tr>
<td>ENSG00000128422.4</td>
<td></td>
<td></td>
<td>Keratin type 1</td>
</tr>
<tr>
<td>ENSG00000182235.1</td>
<td></td>
<td></td>
<td>Coactosin</td>
</tr>
<tr>
<td>ENSG00000128438.1</td>
<td>Q9H7M0</td>
<td></td>
<td>Ubiquitin carboxyl terminal hydrolase</td>
</tr>
<tr>
<td>ENSG00000175061.1</td>
<td>UBB</td>
<td>Ubiquitin</td>
<td>40S ribosomal s27a</td>
</tr>
<tr>
<td>ENSG00000133030.3</td>
<td>NM_015134</td>
<td>Rho interacting protein 3</td>
<td>13B</td>
</tr>
<tr>
<td>ENSG00000179598.1</td>
<td>NM_178836</td>
<td>Similar to CG12314 gene product</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000154803.2</td>
<td>NM_144997</td>
<td>Folliculin isoform 1</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000183815.1</td>
<td>NM_032686</td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000154050.1</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000154051.1</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000175061.1</td>
<td></td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000181350.1</td>
<td></td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000175715.3</td>
<td></td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000182222.1</td>
<td></td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000175662.3</td>
<td>TOM12</td>
<td>Target of myb1-like 2</td>
<td>Target of myb 1 src activating and signalling molecule</td>
</tr>
<tr>
<td>ENSG00000171962.3</td>
<td>NM_031294</td>
<td></td>
<td>E07 gene</td>
</tr>
<tr>
<td>ENSG00000171953.2</td>
<td>ATP5A2</td>
<td>ATP synthase mitochondrial F1 complex assembly factor 2</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000141034.1</td>
<td>NM_024052</td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000108591.2</td>
<td>DRG2</td>
<td>Developmentally regulated GTP binding protein 2</td>
<td>Developmentally regulated GTP binding</td>
</tr>
<tr>
<td>ENSG00000091536.3</td>
<td>MYO15A</td>
<td>Myosin XV</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000091542.1</td>
<td>NM_017578</td>
<td>Alanine rich region/type 1 antifreeze protein</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000131899.2</td>
<td>LLGL1</td>
<td>Lethal giant larvae homologue 1</td>
<td>Lethal 2 giant larvae</td>
</tr>
<tr>
<td>ENSG00000177313.1</td>
<td>FLII</td>
<td>Flightless-I protein homologue</td>
<td>Actin</td>
</tr>
<tr>
<td>ENSG00000177427.3</td>
<td>SMCR7</td>
<td>Smith-Magenis syndrome chromosome region, candidate 5</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000174301.2</td>
<td>TOP3A</td>
<td>DNA topoisomerase III alpha</td>
<td>DNA topoisomerase III</td>
</tr>
<tr>
<td>ENSG00000176994.1</td>
<td>SMCR8</td>
<td>Smith-Magenis syndrome chromosome region, candidate 5</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000175647.2</td>
<td>SHMT1</td>
<td>Serine hydroxymethyltransferase, cysolic</td>
<td>Serine hydroxymethyltransferase</td>
</tr>
<tr>
<td>ENSG00000170292.1</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000183027.2</td>
<td></td>
<td></td>
<td>Ubiquitin carboxyl terminal hydrolase</td>
</tr>
<tr>
<td>ENSG00000131885.3</td>
<td></td>
<td>Keratin type 1</td>
<td>Keratin type 1</td>
</tr>
<tr>
<td>ENSG00000171916.3</td>
<td></td>
<td></td>
<td>Gaeitin</td>
</tr>
<tr>
<td>ENSG00000167494.1</td>
<td>NOS2B</td>
<td>Nitric oxide synthase III</td>
<td>Nitric oxide synthase</td>
</tr>
<tr>
<td>ENSG00000178870.1</td>
<td>NM_024974</td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000170299.2</td>
<td></td>
<td></td>
<td>Ankyrin repeat domain</td>
</tr>
<tr>
<td>ENSG00000160511.1</td>
<td>RPS28</td>
<td>40S ribosomal protein S28</td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000154874.1</td>
<td>NM_182568</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000174977.2</td>
<td></td>
<td></td>
<td>Polyadenylate binding interacting 1</td>
</tr>
<tr>
<td>ENSG00000174969.2</td>
<td>ZNF26</td>
<td>Zinc finger protein 26</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000174973.2</td>
<td></td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000186601.1</td>
<td></td>
<td></td>
<td>Tripartite motif 16 oestrogen responsive b box</td>
</tr>
<tr>
<td>ENSG00000171931.1</td>
<td>C17orf1A</td>
<td>Charcot-Marie-Tooth duplicated region transcript 1</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000171928.1</td>
<td></td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000183105.1</td>
<td></td>
<td></td>
<td>FAM18BS</td>
</tr>
<tr>
<td>ENSG00000141127.1</td>
<td>PRPSA2</td>
<td>Phosphoribosyl pyrophosphate synthetase associated protein 2</td>
<td>Phosphoribosyl pyrophosphate synthetase associated protein 2</td>
</tr>
<tr>
<td>ENSG00000179727.2</td>
<td>Q9N2W8</td>
<td></td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000154052.2</td>
<td>NM_152351</td>
<td></td>
<td>Sodium/glucose cotransporter</td>
</tr>
<tr>
<td>ENSG00000154016.2</td>
<td>GRAP</td>
<td>GRB2-related adaptor protein</td>
<td>Growth factor receptor bound 2 adapter/SH2/SH3 adapter</td>
</tr>
<tr>
<td>ENSG00000072134.3</td>
<td>EPN2</td>
<td>Epsin 2 isoform B</td>
<td>Ambiguous</td>
</tr>
<tr>
<td>ENSG00000108641.1</td>
<td>NM_015681</td>
<td>B9 protein</td>
<td>Unknown</td>
</tr>
<tr>
<td>ENSG00000166484.4</td>
<td>MAPK7</td>
<td>Mitogen-activated protein kinase 7</td>
<td>Mitogen activated kinase</td>
</tr>
<tr>
<td>ENSG00000166482.3</td>
<td>MAPK4</td>
<td>Microfilament associated glycoprotein 4 precursor</td>
<td>Mitogen activated kinase</td>
</tr>
<tr>
<td>ENSG00000128482.2</td>
<td>ZNF179</td>
<td>Zinc finger protein 179</td>
<td>Zinc finger 179 brain finger</td>
</tr>
<tr>
<td>ENSG00000184001.1</td>
<td>Q8R5W5</td>
<td></td>
<td>40S ribosomal S28</td>
</tr>
<tr>
<td>ENSG00000142494.1</td>
<td>NM_018242</td>
<td></td>
<td>Ambiguous</td>
</tr>
</tbody>
</table>
DISCUSSION

Neuroblastoma is a complex disease with diverse clinical behaviour and largely unknown aetiology. Linkage studies in neuroblastoma families have suggested the existence of predisposing gene(s) in chromosomes 4 and 16, but other studies have produced negative results in chromosome 16 and some of the regions commonly altered in neuroblastomas. This suggests that multiple genes could be involved in neuroblastoma development and hence linkage found in some populations might not be detected in other populations. The observation of several deleted regions in neuroblastomas without gene identification raises the possibility that haploinsufficiency might also be involved. Thus, the genetic mechanisms involved in neuroblastoma development need to be clarified further, and additional analyses on neuroblastomas are of great importance as they can lead to better understanding, diagnosis, and management of the disease.

In the present work, we performed genetic analyses on a young patient with advanced stage neuroblastoma and metastasis of the disease. The patient was also diagnosed with SMS. According to prometaphase chromosome analysis, there was a 17p11.2 chromosome deletion in the normal tissue DNA. The deleted region was defined with microsatellite marker analysis and was seen to lie between markers D17S1857 and D17S842.

In neuroblastoma, 17p deletions are rare. However, chromosome 17p11.2 deletions have been frequently observed, for example in childhood primitive neuroectodermal tumours, where the commonly deleted region overlaps with the critical region deleted also in SMS. Although 17p11.2 deletion is a characteristic aberration in SMS patients, there are rare cases where 17p11.2 deletions have not been detected. These cases are phenotypically consistent with SMS, but do not display some of the SMS associated features, such as heart defects or short stature.21 Recently, three such patients were identified with truncating mutations in Rai1, which was later cloned from a neuroblastoma cell line. Rai1 has been associated with neuronal differentiation in mouse studies. Thus Rai1 could be responsible for the behavioural, neurological, otolaryngological, and craniofacial anomalies of SMS, and the other features of this syndrome could result from hemizygosity of other genes in the 17p11.2 region.21

To our knowledge, there have been no reports of tumour predisposition associated with SMS, although the syndrome is characterised by variable phenotypic features. This argues

Table 2  MYCN, Meis1, or TrkA regulated gene expression in SH-EP, SJ-NB8, and SH-SYSY neuroblastoma cell lines

<table>
<thead>
<tr>
<th>Gene</th>
<th>Start position, bp</th>
<th>SAGE tag(s)</th>
<th>SH-EP MYCN</th>
<th>SJ-NB8 Meis1</th>
<th>SH-SYSY TrkA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ubb</td>
<td>16 484 927</td>
<td>GTAGCAAAAA</td>
<td>12 15 12 17 13</td>
<td>Off On Off On Off On</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GTAGCATAAA</td>
<td>32 17 43 57 55 48</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GCATTGGAAG</td>
<td>0 0 12 1 2 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>GCATTGGAAG</td>
<td>0 0 12 1 2 0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>55 29</td>
<td>70 70 74 61</td>
<td>Off On Off On</td>
<td></td>
</tr>
<tr>
<td>Tom1/2</td>
<td>17 950 706</td>
<td>TAAATATCATC</td>
<td>9 0 0 0 2 0</td>
<td>Off On Off On</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TGGCAGCGTG</td>
<td>0 0 0 0 2 0</td>
<td>Off On Off On</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>9 0 0 0 4 0</td>
<td>Off On Off On</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prx2</td>
<td>18 962 058</td>
<td>CTGTTCCTCC</td>
<td>0 0 5 0 0 0</td>
<td>Off On Off On</td>
<td></td>
</tr>
<tr>
<td>Mifap67</td>
<td>19 448 786</td>
<td>AGGAGCCAGA</td>
<td>2 15 12 5 0 21</td>
<td>Off On Off On</td>
<td></td>
</tr>
<tr>
<td>Usp22</td>
<td>21 068 373</td>
<td>GCCTTCGCTT</td>
<td>0 9 6 1 4 4</td>
<td>Off On Off On</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TTTATATAAAAA</td>
<td>2 3 5 0 7 0</td>
<td>Off On Off On</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>2 12 11 1 11 4</td>
<td>Off On Off On</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The SAGE tag frequencies are normalised per 100 000 transcripts in the cell. Potentially relevant gene expression differences are depicted in bold. *Tag can also belong to two other, unrelated genes.
against the existence of important tumour suppressors in the
SMs commonly deleted region. The phenotypic variability of
SMs can perhaps be partly explained by the differences in the
17p11.2 deletion size. The deletion size can vary because of the
occurrence of alternative low copy repeats (LCRs) in the
17p11.2 region.24 LCRs can act as substrates for non-allelic
homologous recombination that results in deletion, duplica-
tion, or inversion of the genomic segments flanked by the
LCRs.25 The deletion detected in our neuroblastoma patient
is larger than those typically seen in SMs patients.26 Thus the
genes locating closer to the deletion breakpoints, rather than the
SMs commonly deleted region, might be of particular
interest for neuroblastoma predisposition.

We analysed the deleted 17p11.2 region further with array
CGH and SAGE. The array CGH data correlated well with the
results obtained from the microsatellite analysis and no other
clear copy number changes were detected in the patient’s
normal tissue DNA. However, most genes within the deleted
region have unknown functions. SAGE data was used to
identify any 17p11.2 genes that could be involved in
neuroblastoma development. The downstream targets of
MYCN, Meis1, and TrkA pathways were examined in three
neuroblastoma cell lines. MYCN and Meis1 are oncogenes, and
their downregulated targets might be associated with
differentiation. Haploinsufficiency of these target genes
due to the deletion could potentially block a differentiation step
and thereby promote pathogenesis of neuroblastoma. TrkA
expression is associated with good prognosis of neuroblas-
toma, and may therefore upregulate genes with differentia-
tion potential. Similarly, a deletion of the upregulated genes
could block differentiation.

The SAGE analyses of the neuroblastoma pathways
identified five genes in the deleted region that could have a
role in neuroblastoma development. MYCN was shown to
regulate the expression of Ubb and Tomil2, which are involved in
protein degradation and trafficking, respectively. An aberrant form of Ubb has also been detected in the
cerebral cortex of Alzheimer’s and Down’s syndrome
patients.27 Other candidate genes downregulated by Meis1
or upregulated by TrkA were Mlap4, Usp22, and Prpsap2, which
have functions related to cell adhesion, protein degradation,
and synthesis of nucleotides and histidine, respectively.28 29

Our SAGE data suggest that these five genes could have a role
in the previously identified neuroblastoma pathways, and fur-
ther analyses of their roles in neuroblastoma may there-
fore be of interest.

In addition to the genes identified by SAGE, one of the
possible candidates within the 17p11.2 region is LGL1, a
human homologue of the Drosophila lethal giant larva
gene, which is associated with neuroblast development in
Drosophila.30 However, LGL1 was not represented in the
array CGH chip or SAGE.

In this paper, we report a germline 17p11.2 deletion in
a neuroblastoma patient who had advanced stage and meta-
static disease but was cured with extensive treatment. No
LOH of the 17p11.2 region was found in a limited set of
sporadic neuroblastomas. As the deletion might be a random
event with no tumorigenic implications, additional samples of
different clinical types need to be analysed to obtain more
detailed information on the possible importance of the
affected region in neuroblastoma development. Although
some attractive candidate genes reside in the deleted region
according to our array CGH analysis and SAGE data, genes
with unknown or less attractive functions also have to be
considered. Genotyping a more extensive neuroblastoma
sample set might aid in confirming the putative association
between 17p11.2 and neuroblastoma, and further fine map
the relevant region to form solid basis for candidate gene
analyses by sequencing and other methods.

ACKNOWLEDGEMENTS
The study was supported by grants from the Academy of Finland

Authors’ affiliations
T Hiiusonen, H Sannikorpi, L A Aaltonen, Department of Medical
Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
P Isokanni, Department of Medical Genetics, The Family Federation of
Finland, Helsinki, Finland
P Isokanni, Department of Pediatric Neurology, Hospital for Children
and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
R Versteeg, Departments of Human Genetics and Pediatric Oncology,
Academic Medical Center, Amsterdam, The Netherlands
K Makalowski, Central Pathology Laboratory, Helsinki University Hospital
Laboratory Diagnostics, Helsinki, Finland

Competing interests: none declared

The first two authors contributed equally to this study.

Correspondence to: L A Aaltonen, Department of Medical Genetics,
Biomedicum Helsinki, P.O. Box 63, FIN-00014 University of Helsinki,
Finland; lauri.aaltonen@helsinki.fi

Received 18 May 2004
Revised 6 August 2004
Accepted 2 September 2004

REFERENCES
1 Elf1o, Sandsted B, Thonell S, Alstron L. Spontaneous regression of stage
2 Florio/1, Migliorati R, Tamburrino O, Pellegrini F, Vecchio P, Buffolano W, De
3 Bown N, Catteril S, Lastowska M, O’Neill S, Pearson AR, Plantz D,
Meadeb M, Dangt6 G, Brinksmidich G, Christiansen H, Laureys G,
Spleman F, Nicholson J, Bernheim A, Betts DR, Vandenseppel J, Van Roy N.
Gain of chromosome arm 17q and adverse outcome in patients with
4 Knudsen AG Jr, Strong LC. Mutation and cancer: neuroblastoma and
5 Maris JM, Weiss MJ, Mosse Y, Goo C, White PE, Mogdony M,
Mirensky T, Brodeur GW, Roobbek TR, Urbanbcek M, Shustermann S. Evidence
for a hereditary neuroblastoma predisposition locus at chromosome 16p12-
6 Perri P, Longo L, Cusano R, McCrindle CM, Rees SA, Devato M, Conte M,
Ferrara GB, Seri M, Romeo G, Tonini GP. Weak linkage at 4p16 to
7 Tonini GP, McCrindle C, Cusano R, Rees SA, Dagino M, Longo L, De
Bernardi B, Conte M, Garraventa A, Romeo G, Davato M, Seri M. Exclusion
of candidate genes and chromosomal regions in familial neuroblastoma.
8 Greenberg F, Guzzetta V, Montes de Oza-Luna R, Magenis RE, Smith AC,
Richer SI, Kondo I, Dobyns WB, Patel P, Lupsiri JR. Molecular analysis of the
Smith-Magenis syndrome: a possible contiguous-gene syndrome associated
9 Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, Killian J, Murphy MA,
Williams D, Brown F, Dutton R, McCullage C, Friedman E, Sulek M,
Lupsiri JR. Multi-disciplinary clinical study of Smith-Magenis syndrome
10 Chen RM, Lupsiri JR, Greenberg F, Lewis RA. Ophthalmic manifestations of
11 Monni O, Barlud M, Mousses S, Kanon J, Sauter G, Heiskanen M,
Paaololo P, Avelo K, Chen Y, Biltmier ML, Kallioniem A. Comprehensive copy
number and gene expression profiling of the 17q23 amplicon in human
12 Jones TA, Floman RH, Senger G, Nizetic D, Sherer D. The homeobox gene
MEIS1 is amplified in WAB-32 and highly expressed in other neuroblastoma
13 Spinkel N, van Sluis P, Beitsma M, Boon K, van Schaik BD, van Kampen AH,
Caran H, Versteeg R. The MEIS1 oncogene is highly expressed in
14 Nakagawara A, Arima-Nakagawara M, Szwarda NJ, Azar CG, Cantor AB,
Brodeur GM. Association between high levels of expression of the TRK gene
15 Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P,
Roobekel I, Wees I, Voute PA, Schwamb M, Versteeg R. The TRK oncogene
expression of a large set of genes functioning in ribosome biogenesis and
16 Geerts D, Schilderk N, Jorritsma G, Versteeg R. The role of the MEIS
17 Feng CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE,
Vogelstein B, Cantor AB, Look AT, Brodeur GM. Loss of heterozygosity for

www.jmedgenet.com


